MK-8719 is an oral O-GlcNAcase (OGA) inhibitor developed by Merck & Co. (known as MSD outside the United States and Canada). It was one of the first brain-penetrant OGA inhibitors to advance to clinical development, completing Phase 1 studies demonstrating target engagement in healthy volunteers[@mk8719_phase1][@kim2020].
MK-8719 represents Merck's entry in the tauopathy therapeutic space, targeting the same O-GlcNAcylation pathway as other OGA inhibitors (FNP-223, LY-3372689) but with distinct pharmaceutical properties designed for optimal brain penetration.
Mechanism of Action
MK-8719 is a potent, selective OGA inhibitor that increases O-GlcNAcylation levels on tau protein:
Target: O-GlcNAcase (OGA) — the enzyme encoded by [MGEA5](/genes/mgea5) that removes O-GlcNAc from proteins
Mechanism: Inhibiting OGA increases tau O-GlcNAcylation at pathological sites (Thr231, Ser396, Ser404)
Effect: O-GlcNAcylated tau is less prone to pathological phosphorylation and aggregation
Outcome: Potential disease modification by reducing toxic tau species
The scientific foundation rests on the yin-yang hypothesis: phosphorylation and O-GlcNAcylation compete for the same serine/threonine residues on tau. By inhibiting OGA, MK-8719 shifts the balance toward protective O-GlcNAcylation[@trapps2023][@yuzwa2012].
Mermaid diagram (expand to render)
Clinical Development
Phase 1 Study (NCT04195312)
The Phase 1 study demonstrated:
MK-8719 was generally well-tolerated at all doses tested
Brain penetration achieved at doses predicted to be therapeutically relevant
Pharmacodynamic effects persisted for 24+ hours post-dose
Clinical Status
As of early 2026, Merck has not announced Phase 2 development plans for MK-8719. Several factors may influence future development decisions:
Competitive landscape: Other OGA inhibitors (LY-3372689, FNP-223) have advanced further in clinical development
Regulatory clarity: FDA guidance on OGA inhibitor development path continues to evolve
Biomarker qualification: CSF O-GlcNAc as a surrogate endpoint still under validation
Strategic priorities: Merck's broader neuroscience portfolio may influence resource allocation
Differentiation from Other OGA Inhibitors
Potential Advantages of MK-8719
High brain penetration: Designed specifically for CNS target engagement
Novel chemical series: Different scaffold from other OGA inhibitors (thiazoline-based vs. others)
Merck resources: Large pharma capabilities for global development if program advances
Development Challenges
Late competition: MK-8719 completed Phase 1 while other programs advanced in Phase 2
Biomarker gap: CSF O-GlcNAc not yet qualified as surrogate endpoint[@west2024]
Uncertainty: No announced path forward for tauopathy indications
Comparison with LY-3372689 (Zaniglusemab)
While MK-8719 is a small molecule OGA inhibitor, Eli Lilly's LY-3372689 (zaniglusemab) is also a small molecule OGA inhibitor that advanced further:
Merck's decision not to advance MK-8719 into Phase 2 may reflect strategic prioritization rather than efficacy concerns, as Phase 1 data demonstrated target engagement.
[Kim et al., Discovery of MK-8719 as a potent brain-penetrant O-GlcNAcase inhibitor (J. Med. Chem., 2020)](https://doi.org/10.1021/acs.jmedchem.0c00789)
[MK-8719 Phase 1 Study (NCT04195312)](https://clinicaltrials.gov/ct2/show/NCT04195312)
[Trapps et al., O-GlcNAcylation in tauopathy: From mechanisms to therapy (Nature Reviews Neurology, 2023)](https://doi.org/10.1038/s41582-023-00765-4)
[Yuzwa et al., Increasing O-GlcNAcylation reduces amyloid and tau pathology (Nature Chemical Biology, 2012)](https://doi.org/10.1038/nchembio.917)
[West et al., Target engagement and biomarkers in OGA inhibitor trials (Alzheimer's & Dementia, 2024)](https://doi.org/10.1002/alz.13657)